Todos os estudos
RecrutamentoFASE2, FASE3INTERVENCIONISTA

A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

We're looking into a new medicine called efgartigimod PH20 SC for young people aged 2 to 17 who have a condition affecting their muscles called generalised Myasthenia Gravis (gMG). This study aims to find the most effective and safest dose for children. We'll be giving participants injections of the medicine and closely watching how their bodies react, how much of the medicine is in their system, and if there are any side effects. The main goal is to figure out the right amount of medicine for children with gMG. Those who complete the main study might have the option to continue with the medicine in a follow-up study.

Em resumo

Status
Recrutamento
Fase
FASE2, FASE3
Patrocinador
argenx
Meta de inscrição
12
Iniciar
28 de jun de 2024
Conclusão estimada
01 Set 2027

Sobre o que é este estudo?

This research is looking at a new treatment called efgartigimod PH20 SC for children and teenagers between 2 and 17 years old who have generalised Myasthenia Gravis (gMG). gMG is a condition that causes muscle weakness. Even though you might already be taking other medicines for your gMG, this study is for those who haven't found enough relief from their current treatments.

The main purpose of this study is to understand how this new medicine works in young people. We want to learn how the body uses and processes the medicine, what effects it has, and importantly, to make sure it's safe and well-tolerated. Finding the right dose for children is really important because medicines can affect children differently than adults.

Over a period of up to 14 weeks, participants will receive the efgartigimod PH20 SC medicine as injections. The research team will regularly check on their health and monitor for any side effects. At the end of these 14 weeks, if the medicine is helping and suitable, some participants might be able to continue receiving the treatment in a longer-term follow-up study, which is called an open-label extension study.

Pontos principais

  • This study is for children aged 2-17 with generalised Myasthenia Gravis.
  • It's testing a new injection called efgartigimod PH20 SC.
  • The main goals are to find the right dose and check its safety.
  • Participants will have regular check-ups over 14 weeks.
  • Você pode parar de participar a qualquer momento.
  • Your child will still take their current MG medicines if they are on a stable dose.

Quem pode ser elegível?

To join this study, a young person must be between 2 and 17 years old. They need to have been diagnosed with generalised Myasthenia Gravis, and doctors must have found specific antibodies in their blood. Also, their current treatments for Myasthenia Gravis shouldn't be working well enough for them, but they need to be on a steady dose of these existing medicines for at least a month before joining.

There are also some things that would mean someone cannot take part. For example, if a young woman could become pregnant, she cannot be pregnant or breastfeeding, and must agree to use effective birth control during the study. Participants cannot have certain other medical conditions or have had particular treatments recently, like some vaccinations, or surgery on their thymus gland in the last three months.

The study also cannot include anyone who has worsening muscle weakness due to an infection or another medicine, or if their Myasthenia Gravis didn't improve after a specific treatment called plasma exchange (PLEX). If they've had cancer, they usually need to have been free of it for at least three years, though some types of skin cancer might be an exception.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Is your child aged between 2 and 17 years old?
  2. Does your child have a diagnosis of generalised Myasthenia Gravis confirmed by a blood test?
  3. Are your child's current Myasthenia Gravis medications not fully controlling their symptoms, but they have been on a stable dose for at least a month?
  4. Is your child not currently pregnant, breastfeeding, or planning to become pregnant during the study?
  5. Has your child not had thymus gland surgery in the last 3 months?
  6. Does your child not have new muscle weakness from an infection or other medication?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you decide to take part, you or your child will be in the study for up to 14 weeks. During this time, they will receive injections of the study medicine, efgartigimod PH20 SC. The research team will arrange for regular check-ups to see how the medicine is affecting your child, track how much of it is in their body, and look for any side effects. This involves visits to the clinic for assessments and monitoring. After the 14 weeks, if suitable, there might be an option to continue the treatment in a follow-up study.

Riscos e benefícios potenciais

Taking part in this study could potentially offer your child access to a new treatment that might help with their generalised Myasthenia Gravis, especially if current medicines aren't working well enough. However, like all medicines, there could be side effects or risks that we don't fully know about yet in children. The study team will explain all known risks. Remember, taking part is completely voluntary, and you are free to withdraw from the study at any time without giving a reason, and this won't affect your child's usual medical care.

Localizações (22)

  • Carolinas HealthCare System Neurosciences Institute - Neurology
    Código postal verificado
    Charlotte, Estados Unidos· Ativo, mas não recrutando
  • Neurology Rare Disease Center
    Código postal verificado
    Denton, United States· Ativo, mas não recrutando
  • University of Virginia
    Código postal verificado
    Charlottesville, United States· Ativo, mas não recrutando
  • Royal Children's Hospital Melbourne
    Aproximado
    Melbourne, Austrália· Recrutamento
  • Sydney Children's Hospital
    Código postal verificado
    Randwick, Austrália· Recrutamento
  • UZ Gent
    Código postal verificado
    Gante, Bélgica· Recrutamento
  • Childrens Hospital of Eastern Ontario
    Código postal verificado
    Ottawa, Canadá· Recrutamento
  • Fakultni nemocnice Brno
    Código postal verificado
    Brno, Tchéquia· Recrutamento
  • Fakultni nemocnice Ostrava
    Código postal verificado
    Ostrava, Czechia· Recrutamento
  • AP-HM- Hôpital de La Timone
    Código postal verificado
    Marselha, França· Recrutamento
  • Universitätsklinikum Essen
    Código postal verificado
    Essen, Alemanha· Recrutamento
  • Hadassah Medical Center- Ein Kerem
    Código postal verificado
    Jerusalem, Israel· Recrutamento

Perguntas frequentes

What is generalised Myasthenia Gravis?

It's a condition that causes muscles to become weak and tired, making everyday tasks harder.

What is efgartigimod PH20 SC?

It's a new medicine being tested as an injection for people with generalised Myasthenia Gravis.

Quanto tempo durará o estudo?

Each participant will be in the main part of the study for up to 14 weeks.

Will my child still take their usual Myasthenia Gravis medicines?

Yes, your child will likely stay on their usual medicines, but these need to be at a stable dose before the study starts.

Posso sair do estudo a qualquer momento?

Yes, you can choose to withdraw from the study at any point, and it won't affect your child's regular medical care.

Como saber mais

Sabine Coppieters, MD

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "A Study of Efgartigimod PH20 SC in Children Between 2 and Le…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.